UNSPSC 51332872: Propiomazine hydrochloride

This classification denotes an antipsychotic agent with the molecular formula C20H24N2OS.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 70BO17YR03, chemically known as 1-propanone, 1-(10-(2-(dimethylamino)propyl)-10h-phenothiazin-2-yl)-, monohydrochloride but more generally known as propiomazine hydrochloride, which bears US NIH Compound Identifier 71802. European Medicines Agency schedules Propiomazine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04083MIG.

UNSPSC 51332872 Propiomazine hydrochloride is a Commodity code that captures pharmaceutical products procured by state and local health agencies, though recent solicitations under this code tag a broader range of pharmaceutical procurement activity than propiomazine specifically. State and local governments are buying generic multi-source pharmaceuticals, naloxone, OTC products, and direct-to-manufacturer prescription fulfillment capability under codes tagged with this designation. The issuing bodies include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances that aggregate demand across state and local members. Seminole County, Florida; Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) are current active buyers, with MMCAP serving participating state and local facilities across Minnesota, Oregon, and subordinate jurisdictions.

Recent activity spans Florida, Texas, and Minnesota. Seminole County posted IFB 60459723LAS on June 30, 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response deadline July 26, 2023 (note: deadline date appears to be misdated in the source relative to posting date). Texas HHS issued RFI HHS0017013 on April 3, 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, a market-intelligence mechanism to inform future formal procurement. MMCAP released RFP S1070000015802 on January 20, 2026 for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. All three solicitations impose standard state and local compliance requirements including E-Verify, drug-free workplace certification, insurance coverage, FDA compliance, and manufacturing practice standards (cGMP and DSCSA for MMCAP). Pricing evaluation weights competitiveness heavily; MMCAP explicitly weights price at 75 percent of the evaluation score.